NCT04838899View on ClinicalTrials.gov

Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 16, 2016

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
OligoprogressiveCastration-Resistant Prostate Cancer
Interventions
RADIATION

Stereotactic Body Radiation Therapy (SABR)

SABR to oligoprogressive metastases while continuing abiraterone therapy

Trial Locations (1)

M4N3M5

RECRUITING

Odette Cancer Centre, Toronto

All Listed Sponsors
lead

Sunnybrook Health Sciences Centre

OTHER